

I. AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-20. (Cancelled)

21. (Currently amended) A method of delivering recombinant adeno-associated virus virions to the brain of a subject suffering from a central nervous system (CNS) disorder, comprising:

(a) providing a ~~pharmaceutical~~ composition comprising recombinant adeno-associated virus virions, said recombinant adeno-associated virus virions encoding a protein; and

(b) administering said composition to the brain of the subject such that distribution of said recombinant adeno-associated virus virions over an area greater than 5 mm² is achieved, wherein said recombinant adeno-associated virus virions are administered by convection enhanced delivery using a pump.

22. (Cancelled)

23. (Currently amended) The method of claim ~~22~~ 21, wherein said convection enhanced delivery is performed using an infusion pump.

24. (Currently amended) The method of claim ~~22~~ 21, wherein said convection enhanced delivery is performed using an osmotic pump.

25. (Previously presented) The method of claim 21, wherein said recombinant adeno-associated virus virions are administered to the striatum.

26. (Currently amended) The method of claim ~~23~~ 21, wherein distribution of said recombinant adeno-associated virus virions is over an area of at least ~~40-50 mm²~~ about 50 mm².

27. (Currently amended) The method of claim ~~24~~ 23, wherein distribution of said recombinant adeno-associated virus virions is over an area of at least ~~40-50 mm²~~ about 50 mm².

28. (New) The method of claim 24, wherein distribution of said recombinant adeno-associated virus virions is over an area of at least about 50 mm².

29. (New) A method of delivering recombinant adeno-associated virus virions to the brain of a subject suffering from a central nervous system (CNS) disorder, comprising:

(a) providing a composition comprising recombinant adeno-associated virus virions, said recombinant adeno-associated virus virions encoding a protein; and

(b) administering said composition to the brain of the subject at a rate of 0.4 µl per minute or less such that distribution of said recombinant adeno-associated virus virions over an area greater than 5 mm² is achieved.

30. (New) The method of claim 29, wherein said recombinant adeno-associated virus virions are administered using convection enhanced delivery (CED) using a means for CED pumping.

31. (New) The method of claim 30, wherein said convection enhanced delivery is performed using an infusion pump.

32. (New) The method of claim 30, wherein said convection enhanced delivery is performed using an osmotic pump.

33. (New) The method of claim 29, wherein said composition is administered at a rate of 0.2 µl per minute or less.

34. (New) The method of claim 29, wherein said composition is administered at a rate 0.1 μ l per minute or less.